论文部分内容阅读
本刊讯2015年12月14日,英国药品和健康产品管理局(MHRA)发布信息,75岁以上患者使用沙利度胺时应降低起始剂量。在年龄75岁以上的患者中,最新推荐的沙利度胺起始剂量应为每天100 mg,以尽量降低药品不良反应发生的风险。在年龄75岁或以下的患者中推荐的沙利度胺起始剂量仍为每日200 mg。在英国,沙利度胺联合美法仑和泼尼松适用于年龄65岁或以上初次治疗多发性骨髓瘤患者的一线治疗,
On December 14, 2015, the British Agency for Medicines and Health Products (MHRA) released information that the initial dose should be lowered when using thalidomide in patients over 75 years of age. In patients over the age of 75 years, the latest recommended thalidomide initial dose should be 100 mg daily to minimize adverse drug reactions occur risk. The initial thalidomide dose recommended for patients aged 75 years and under is still 200 mg daily. In the UK, thalidomide combined with melphalan and prednisone is suitable for first-line treatment of patients with multiple myeloma who are 65 years of age or older,